TransMedics Announces Gerardo Hernandez as New CFO Along with Financial Outlook for 2024

TransMedics Appoints Gerardo Hernandez as CFO

TransMedics Group, Inc. is making waves in the medical technology sector with the recent announcement of Gerardo Hernandez as Chief Financial Officer, effective December 2, 2024. This decision comes as part of the company's strategy to bolster its executive team and enhance its financial leadership as it strives to redefine organ transplant therapy.

Hernandez brings with him an impressive background, having accumulated over 25 years of experience in finance, specifically within the healthcare and consumer packaged goods sectors. His most recent role was at Alnylam Pharmaceuticals where he served as the Vice President of Finance, heading corporate financial planning and analysis. Here, Hernandez was pivotal in leading a global team that supported rapid company growth. Before this, he spent nearly a decade at Shire, playing a key role through its transition following a massive acquisition by Takeda valued at $62 billion.

Dr. Waleed Hassanein, President and CEO of TransMedics, expressed gratitude towards Stephen Gordon, the outgoing CFO, for his dedicated service over almost a decade. Gordon’s expertise was vital in transitioning TransMedics from a clinical-stage company to a significant player in the public market. To ensure a seamless transition, Gordon will remain with the company in a non-executive capacity until March 31, 2025, after which he will continue to provide advisory services focused on national transplant engagements.

In a statement, Hernandez expressed enthusiasm about joining TransMedics, emphasizing the company's commitment to enhancing access to its unique products and services in the organ transplant field while improving operational efficiency. This aligns with the broader mission of TransMedics to address the critical need for better organ transplant options for patients facing end-stage lung, heart, and liver diseases.

Furthermore, a revamped financial outlook for 2024 was revealed, projecting a revenue range of $428 million to $432 million—marking a growth of 77% to 79% compared to the previous year. This optimistic forecast exemplifies the company’s confidence in its ongoing initiatives and evolving strategic vision.

TransMedics will further discuss this transition and future financial strategies at the upcoming Investor Analyst Day scheduled for December 10, 2024, in New York City. This significant event will delve deeper into the company's growth strategy as well as its clinical pipeline and operations, paving the way for new opportunities and discussions among investors and analysts alike.

For those interested in more details, Hernandez and other members of the management team will also partake in discussions at the Piper Sandler Healthcare Conference taking place on December 3, 2024, offering insights into the company’s trajectory and market positioning.

As TransMedics embarks on this new chapter with Gerardo Hernandez at the financial helm, the medical technology sector is poised for further innovations and advancements that could transform patient care and organ transplant therapies on a global scale.